Breaking News

Catalent, Adamas Enter CTM Agreement

By Kristin Brooks | January 8, 2014

Catalent to manufacture ADS-5102 for Phase III trials

Catalent Pharma Solutions and Adamas Pharmaceuticals have entered an agreement for the manufacture of ADS-5102 (amantadine HCl) extended release capsules for Phase III trials. ADS-5102 is an investigational drug being developed for Levodopa-Induced Dyskinesia (LID) in patients with Parkinson’s disease.
 
“We believe Catalent’s capabilities make them the right choice to support execution of our upcoming clinical trials,” said Gregory T. Went, Ph.D., Adamas chairman and chief executive officer.
 
Barry Littlejohns, president of Catalent’s Advanced Delivery Technologies business, said, “Our controlled release formulation expertise and drug delivery technologies will ultimately benefit patients with better treatments. We are pleased Adamas selected Catalent for the development and supply of ADS-5102 which, if approved, will be the first medical treatment indicated for patients with LID in Parkinson’s disease.”

blog comments powered by Disqus
  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016